Work

Multicenter randomized phase II trial of cisplatin, irinotecan plus bevacizumab (PCA) versus docetaxel, cisplatin, irinotecan plus bevacizumab (TPCA) in patients (pts) with metastatic esophagogastric cancer (MEGCA).

Year: 2012

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2012.30.15_suppl.4027

Authors: Peter C. Enzinger, Eunice Lee Kwak, Jackie Szymonifka, Thomas Adam Abrams, Eileen Regan, Paige Malinowski, Kent C. Shih, Jill N. Allen, Nadine Jackson, Jennifer A. Chan, Panos Fidias, David P. Ryan, Charles S. Fuchs, Johanna C. Bendell

Institutions: Dana-Farber Cancer Institute, Massachusetts General Hospital, Sarah Cannon, Tennessee Oncology

Language: English

Topic: Gastric Cancer Management and Outcomes

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2596520486

Cites:

Cited by: 3

Related to: 10